Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020)

Historic Liabilities from Discontinued Operations for Agios Pharmaceuticals (AGIO) over the last 1 years, with Q4 2020 value amounting to $261.3 million.

  • Agios Pharmaceuticals' Liabilities from Discontinued Operations changed N/A to $261.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $261.3 million, marking a year-over-year change of. This contributed to the annual value of $261.3 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Liabilities from Discontinued Operations of $261.3 million as of Q4 2020.
  • In the past 5 years, Agios Pharmaceuticals' Liabilities from Discontinued Operations ranged from a high of $261.3 million in Q4 2020 and a low of $261.3 million during Q4 2020